Why Its Important: Semaglutide is a powerful tool, but long-term success requires lifestyle changes
Visual Field Defects Visual field defects (independent of elevated intraocular pressure) have been reported in clinical trials and in postmarketing experience in patients receiving topiramate
A gap might be an unclear product form, a COA that does not match the lot, a missing method description, or supplier copy that conflicts with RUO positioning
Yasin, H., Tariq, F., Sameen, A., Ahmad, N., Manzoor, M
The STEP trials demonstrated that semaglutide produces an average 15% body weight reduction over 68 weeks in patients with obesity, with some individuals losing up to 22% of their starting weight
This review has two main strengths